Metraipolis › archive › dc_db583d0f66ec
Adverse and Serious Adverse Events Associated With Tocilizumab in COVID-19 Pneumonia and With Cyclosporin, Pazopanib, and Insulin Glargine in Other Diseases:… — Europe PMC PMID:41884321
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41884321
- DOI
- 10.7759/cureus.105738
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-04T02:44:08.728Z
- SHA-256 of the archived text
8446173f6f92335a51e96b3757d023d9dcb940fa625049f72fd2614eb92a64aa- Stable URL of this page
https://metraipolis.com/documento/dc_db583d0f66ec
How to cite
Adverse and Serious Adverse Events Associated With Tocilizumab in COVID-19 Pneumonia and With Cyclosporin, Pazopanib, and Insulin Glargine in Other Diseases:… — Europe PMC PMID:41884321 — Europe PMC (en), https://europepmc.org/article/MED/41884321 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_db583d0f66ec (Metraipolis archive dc_db583d0f66ec, sha256 8446173f6f92335a51e96b3757d023d9dcb940fa625049f72fd2614eb92a64aa)
BibTeX
@misc{dcdb583d0f66ec,
title = {Adverse and Serious Adverse Events Associated With Tocilizumab in COVID-19 Pneumonia and With Cyclosporin, Pazopanib, and Insulin Glargine in Other Diseases:… — Europe PMC PMID:41884321},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41884321},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_db583d0f66ec; sha256 8446173f6f92335a51e96b3757d023d9dcb940fa625049f72fd2614eb92a64aa},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41884321. Agents can read the archived copy with the MCP tool read_document.